SWOG 1815: gemcitabine, cisplatin, and nab-paclitaxel in biliary tract cancer
Rachna Shroff, MD, MS, University of Arizona College of Medicine, Tucson, AZ, presents findings from the Phase III SWOG 1815 trial (NCT03768414) of gemcitabine, cisplatin, and nab-paclitaxel in newly diagnosed, advanced biliary tract cancers. 441 patients were randomized to receive the investigational regimen or the standard of care (gemcitabine and cisplatin). Whilst overall survival (OS) was higher in patients receiving gemcitabine, cisplatin, and nab-paclitaxel, it was not statistically significant. OS was also marginally improved in patients with gallbladder cancer, and a number of grade 3-5 adverse events were reported. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
No comments found